Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment 13474464

Koichiro Komai, Kazuko Shiozawa, Yasushi Tanaka, Ryosuke Yoshihara, Chihiro Tanaka, Hideo Sakai, Takashi Yamane, Miki Murata, Ken Tsumiyama, Akira Hashiramoto, Shunichi Shiozawa

研究成果: ジャーナルへの寄稿記事

7 引用 (Scopus)

抄録

Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by sicca symptoms, including dry eyes and dry mouth. Cevimeline is used for the treatment of dry mouth in patients with SS. Here we prospectively tested the clinical effectiveness of cevimeline at increasing saliva secretion in patients with SS, and the results were compared with the clinical parameters of the patients. Saliva secretion was increased >160% in 17 of 30 (56.7%) patients (P < 0.005). When the clinical parameters were compared between the patients who responded to cevimeline treatment and those who did not respond to the treatment, the frequency of patients presenting with hypergammaglobulinemia was significantly higher in the nonresponder group (P < 0.05). It thus appears that cevimeline is effective in SS patients with milder disease activity.

元の言語英語
ページ(範囲)416-419
ページ数4
ジャーナルModern Rheumatology
19
発行部数4
DOI
出版物ステータス出版済み - 5 19 2009

Fingerprint

Hypergammaglobulinemia
Saliva
Therapeutics
Mouth
cevimeline
Autoimmune Diseases

All Science Journal Classification (ASJC) codes

  • Rheumatology

これを引用

Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment 13474464. / Komai, Koichiro; Shiozawa, Kazuko; Tanaka, Yasushi; Yoshihara, Ryosuke; Tanaka, Chihiro; Sakai, Hideo; Yamane, Takashi; Murata, Miki; Tsumiyama, Ken; Hashiramoto, Akira; Shiozawa, Shunichi.

:: Modern Rheumatology, 巻 19, 番号 4, 19.05.2009, p. 416-419.

研究成果: ジャーナルへの寄稿記事

Komai, K, Shiozawa, K, Tanaka, Y, Yoshihara, R, Tanaka, C, Sakai, H, Yamane, T, Murata, M, Tsumiyama, K, Hashiramoto, A & Shiozawa, S 2009, 'Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment 13474464', Modern Rheumatology, 巻. 19, 番号 4, pp. 416-419. https://doi.org/10.1007/s10165-009-0176-y
Komai, Koichiro ; Shiozawa, Kazuko ; Tanaka, Yasushi ; Yoshihara, Ryosuke ; Tanaka, Chihiro ; Sakai, Hideo ; Yamane, Takashi ; Murata, Miki ; Tsumiyama, Ken ; Hashiramoto, Akira ; Shiozawa, Shunichi. / Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment 13474464. :: Modern Rheumatology. 2009 ; 巻 19, 番号 4. pp. 416-419.
@article{bfcbddf2f55b4364939fddd3e2ed12de,
title = "Sj{\"o}gren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment 13474464",
abstract = "Sj{\"o}gren's syndrome (SS) is a systemic autoimmune disease characterized by sicca symptoms, including dry eyes and dry mouth. Cevimeline is used for the treatment of dry mouth in patients with SS. Here we prospectively tested the clinical effectiveness of cevimeline at increasing saliva secretion in patients with SS, and the results were compared with the clinical parameters of the patients. Saliva secretion was increased >160{\%} in 17 of 30 (56.7{\%}) patients (P < 0.005). When the clinical parameters were compared between the patients who responded to cevimeline treatment and those who did not respond to the treatment, the frequency of patients presenting with hypergammaglobulinemia was significantly higher in the nonresponder group (P < 0.05). It thus appears that cevimeline is effective in SS patients with milder disease activity.",
author = "Koichiro Komai and Kazuko Shiozawa and Yasushi Tanaka and Ryosuke Yoshihara and Chihiro Tanaka and Hideo Sakai and Takashi Yamane and Miki Murata and Ken Tsumiyama and Akira Hashiramoto and Shunichi Shiozawa",
year = "2009",
month = "5",
day = "19",
doi = "10.1007/s10165-009-0176-y",
language = "English",
volume = "19",
pages = "416--419",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment 13474464

AU - Komai, Koichiro

AU - Shiozawa, Kazuko

AU - Tanaka, Yasushi

AU - Yoshihara, Ryosuke

AU - Tanaka, Chihiro

AU - Sakai, Hideo

AU - Yamane, Takashi

AU - Murata, Miki

AU - Tsumiyama, Ken

AU - Hashiramoto, Akira

AU - Shiozawa, Shunichi

PY - 2009/5/19

Y1 - 2009/5/19

N2 - Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by sicca symptoms, including dry eyes and dry mouth. Cevimeline is used for the treatment of dry mouth in patients with SS. Here we prospectively tested the clinical effectiveness of cevimeline at increasing saliva secretion in patients with SS, and the results were compared with the clinical parameters of the patients. Saliva secretion was increased >160% in 17 of 30 (56.7%) patients (P < 0.005). When the clinical parameters were compared between the patients who responded to cevimeline treatment and those who did not respond to the treatment, the frequency of patients presenting with hypergammaglobulinemia was significantly higher in the nonresponder group (P < 0.05). It thus appears that cevimeline is effective in SS patients with milder disease activity.

AB - Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by sicca symptoms, including dry eyes and dry mouth. Cevimeline is used for the treatment of dry mouth in patients with SS. Here we prospectively tested the clinical effectiveness of cevimeline at increasing saliva secretion in patients with SS, and the results were compared with the clinical parameters of the patients. Saliva secretion was increased >160% in 17 of 30 (56.7%) patients (P < 0.005). When the clinical parameters were compared between the patients who responded to cevimeline treatment and those who did not respond to the treatment, the frequency of patients presenting with hypergammaglobulinemia was significantly higher in the nonresponder group (P < 0.05). It thus appears that cevimeline is effective in SS patients with milder disease activity.

UR - http://www.scopus.com/inward/record.url?scp=68549130610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68549130610&partnerID=8YFLogxK

U2 - 10.1007/s10165-009-0176-y

DO - 10.1007/s10165-009-0176-y

M3 - Article

VL - 19

SP - 416

EP - 419

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 4

ER -